ECSP993095A - 1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS) - Google Patents
1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS)Info
- Publication number
- ECSP993095A ECSP993095A ECSP993095A ECSP993095A EC SP993095 A ECSP993095 A EC SP993095A EC SP993095 A ECSP993095 A EC SP993095A EC SP993095 A ECSP993095 A EC SP993095A
- Authority
- EC
- Ecuador
- Prior art keywords
- aryl
- respiratory
- disease
- naftiridin
- onas
- Prior art date
Links
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de fórmula (gráfico), o la sal farmacéuticamente aceptable del mismo, en la que R1, R2 y R3 son como se han definido anteriormente, útil en el tratamiento de trastornos respiratorios, alérgicos, reumatoides, de regulación del peso corporal, inflamatorios y del sistema nerviosos central, tales como asma, enfermedad pulmonar obstructiva crónica, síndrome de enfermedades respiratorias en adultos, choque tóxico, fibrosis, hipersensibilidad pulmonar, rinitis alérgica, dermatitis atópica, psoriasis, control de peso, artritis reumatoide caquexia, enfermedad de Crohn, colitis ulcerosa, afecciones artriticas y otras enfermedades inflamatorias, depresión, demencia multiinfarto y SIDA.A compound of formula (graph), or the pharmaceutically acceptable salt thereof, in which R1, R2, and R3 are as defined above, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulating, inflammatory disorders and of the central nervous system, such as asthma, chronic obstructive pulmonary disease, respiratory illness syndrome in adults, toxic shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993095 ECSP993095A (en) | 1999-08-11 | 1999-08-11 | 1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993095 ECSP993095A (en) | 1999-08-11 | 1999-08-11 | 1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993095A true ECSP993095A (en) | 1999-10-06 |
Family
ID=42044082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993095 ECSP993095A (en) | 1999-08-11 | 1999-08-11 | 1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS) |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993095A (en) |
-
1999
- 1999-08-11 EC ECSP993095 patent/ECSP993095A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810733A (en) | Nicotinamide derivatives | |
| SV1999000120A (en) | 1-ARIL-3-ARILMETIL-1,8-NAFTIRIDIN-4 (1H) -ONAS REF. PC10020 / 82739 / BB | |
| EP1541574A4 (en) | Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient | |
| ECSP055768A (en) | CONDENSED AZOL-PYRIMIDINE DERIVATIVES | |
| TNSN07098A1 (en) | 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| NO20075696L (en) | Nanoparticulated controlled release preparations comprising cyclosporin | |
| PE20060078A1 (en) | PYRAZOLO [3,4-B] PYRIDINE COMPOUND AS INHIBITOR OF TYPE IV PHOSPHODIESTERASE | |
| EP1262475A4 (en) | Indole derivatives, process for preparation of the same and use thereof | |
| TNSN08131A1 (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| AR062051A1 (en) | 2-PHENYLINDOLS AS ANTAGONISTS OF PROSTAGLANDINA D₂ RECEPTOR | |
| AR060403A1 (en) | AMINO COMPOUNDS- PYRIMIDINE 2.6- SUBSTITUTES -4- MONOSUSTITUTES AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER | |
| TW200639151A (en) | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | |
| WO2007114848A3 (en) | Chemical compounds | |
| ECSP993095A (en) | 1-ARYL-3- ARYL METHYL -8 -NAFTIRIDIN -4 (1H) - (ONAS) | |
| WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
| JP2008526953A5 (en) | ||
| EP1666473A4 (en) | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | |
| WO2007062318A3 (en) | Chemical compounds | |
| ECSP982468A (en) | NICOTINAMIDE DERIVATIVES | |
| WO2017126700A9 (en) | Inhibitor of activity of vesicular nucleotide transporter | |
| EP1621540A4 (en) | Nitrogen-containing heterocyclic compounds and use thereof | |
| JP2006502171A5 (en) | ||
| IL185010A0 (en) | Nk1 antagonists | |
| Bermudez et al. | Liposome-ciprofloxacin inhibits Mycobacterium avium subs hominissuis (MAH) microaggregate formation in a dose and time dependent manner |